rather backwards....... CEO Will Lewis initially said that if the C F results were compelling
they could be used to allow NTM to skip a Phase3 trial. The results were ok.
That was before the FDA threw them some -possible- advantages.
The FDA gave Insmed their C F marching orders a long time ago and Insmed chanced it on a shorter trial in Europe that came up short for "compelling"
As of now- Insmed plans not to enter the U.S. market and has stated so numerous times in Investor presentations.
Most all agree NTM is the ballgame Good Luck